NDLI: Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.

Please wait, while we are loading the content...

Year: 2016 Volume: 14

Year: 2015 Volume: 13

Year: 2014 Volume: 12

Year: 2013 Volume: 11

Year: 2012 Volume: 10

Year: 2012 Volume: 10 Issue: 4

Year: 2012 Volume: 10 Issue: 3

Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt.

A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab.

Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier?

A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.

Metastatic extraosseous Ewing's sarcoma (EES)/primitive neuroectodermal tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy.

A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.

The role of IMiDs alone or in combination in prostate cancer.

Trends in the use of cytoreductive nephrectomy in the United States.

Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.

What is the role of enlarged lymph node resection alone in patients with nonseminomatous germ cell tumor who had stage II or III disease?

Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.

Year: 2012 Volume: 10 Issue: 2

Year: 2012 Volume: 10 Issue: 1

Year: 2011 Volume: 9

Year: 2010 Volume: 8

Year: 2009 Volume: 7

Year: 2008 Volume: 6

Year: 2007 Volume: 5

Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Guillot, Aline Levy, Antonin Pacaut, Cécile Collard, Olivier Massard, Christophe Merrouche, Yacine Magné, Nicolas
Description	Country affiliation: France Author Affiliation: Guillot A ( Department of Medical Oncology, Institut de Cancérologie de la Loire, St-Priest en Jarez, France.)
Abstract	Increased understanding of the molecular pathophysiology of metastatic renal cell carcinoma (mRCC) has led to development of antiangiogenic therapies in the past 5 years that significantly improved the prognosis. Vascular endothelial growth factor (VEGF) is a major growth factor in tumor angiogenesis and is implicated in tumor progression of several types of cancer, including mRCC. Use of 2 distinct approaches resulted in clinical efficacy in blocking the VEGF pathway: small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, axitinib, pazopanib) and the humanized anti-VEGF monoclonal antibody bevacizumab that binds circulating VEGF and prevents activation of the VEGF receptor. In the 2 large phase III trials AVOREN and CALGB 90206, bevacizumab combined with interferon alfa demonstrated its efficacy as a first-line therapy in terms of progression-free survival. Nevertheless, in the era of targeted therapies, other studies are still needed to better obtain the maximal clinical benefit of bevacizumab. The aim of this overview is to report the current role of bevacizumab in the treatment of metastatic kidney cancer and to highlight possible combinations or sequential strategies that involve other targeted agents.
File Format	HTM / HTML
ISSN	15587673
Issue Number	3
Volume Number	10
e-ISSN	19380682
Journal	Clinical Genitourinary Cancer
Language	English
Publisher	Elsevier
Publisher Date	2012-09-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Urology Discipline Oncology Angiogenesis Inhibitors Therapeutic Use Antibodies, Monoclonal, Humanized Carcinoma, Renal Cell Drug Therapy Kidney Neoplasms Adverse Effects Antineoplastic Combined Chemotherapy Protocols Bevacizumab Secondary Clinical Trials As Topic Humans Pathology Molecular Targeted Therapy Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Urology Oncology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in